Vuran Gamze, Berdeli Afig
Department of General Pediatrics, Ege University School of Medicine, İzmir, Turkey.
Department of Pediatrics, Divisionof Molecular Biology, Ege University School of Medicine, İzmir, Turkey.
Eur J Rheumatol. 2022 Apr;9(2):62-67. doi: 10.5152/eurjrheum.2022.21049.
Objective: In this study, we aimed to evaluate other interleukin-1b-mediated monogenic autoinflam- matory diseases (AIDs) (tumor necrosis factor receptor-1-associated periodic syndrome, hyperimmuno- globulin D syndrome, cryopyrin-associated periodic syndrome (CAPS), pyogenic arthritis, pyoderma gangrenosum, and acne syndrome) by the next-generation sequencing method (NGS) in cases with clinical Familial Mediterranean Fever symptoms, and no variant detected in the MEFV gene. Methods: The cases included in this study and their parents were interviewed and filled in a survey form. The targeted genetic panel for interleukin-1b-mediated AIDs covering four genes (MVK, NLRP3,TNFRSF1A, and PSTPIP1) was studied for cases with a negative result from the MEFV gene analysis. The genetic analysis was conducted using the targeted NGS method. Results: Variants were found in 16 out of the 40 patients in the study sample. These variants were pri- orly reported in variant databases, and three of them were identified as definitely pathogenic (V377I of the MVK gene, C52Y of the TNFRSF1A gene, and I313V of the NLRP3 gene), four as a variant of uncer- tain significance (VUS) (R92Q of the TNFRSF1A, A372V of the PSTPIP1, and V198M and Q703K of the NLRP3), and one as benign polymorphism (S52N of the MVK gene). The median age of onset among variant-positive cases was 10.5 (3.5-18) years. The most common clinical findings in the variant-positive group were arthralgia, fever, and abdominal pain. While three out of 40 patients met the classification criteria before genetic analysis, only one patient was diagnosed with CAPS as a result of genetic analy- sis, and other patients were considered as nonspecific phenotype. Conclusion: The use of NGS gene panels seems beneficial in diseases with heterogeneous clinical manifestations such as systemic AIDs. Although the number of variants detected is high, clinical diag- nosis rates remain low. The genotype–phenotype relationship in these diseases is still unclear.
在本研究中,我们旨在通过下一代测序方法(NGS)评估临床有家族性地中海热症状且MEFV基因未检测到变异的病例中其他白细胞介素-1β介导的单基因自身炎症性疾病(AIDs)(肿瘤坏死因子受体-1相关周期性综合征、高免疫球蛋白D综合征、冷吡啉相关周期性综合征(CAPS)、化脓性关节炎、坏疽性脓皮病和痤疮综合征)。方法:对本研究纳入的病例及其父母进行访谈并填写调查问卷。对MEFV基因分析结果为阴性的病例研究覆盖四个基因(MVK、NLRP3、TNFRSF1A和PSTPIP1)的白细胞介素-1β介导的AIDs靶向基因panel。采用靶向NGS方法进行基因分析。结果:研究样本中的40例患者中有16例发现变异。这些变异先前已在变异数据库中报道,其中3例被确定为明确致病(MVK基因的V377I、TNFRSF1A基因的C52Y和NLRP3基因的I313V),4例为意义未明的变异(VUS)(TNFRSF1A的R92Q、PSTPIP1的A372V以及NLRP3的V198M和Q703K),1例为良性多态性(MVK基因的S52N)。变异阳性病例的发病年龄中位数为10.5(3.5 - 18)岁。变异阳性组最常见的临床表现为关节痛、发热和腹痛。40例患者中有3例在基因分析前符合分类标准,基因分析结果仅1例被诊断为CAPS,其他患者被认为是非特异性表型。结论:对于系统性AIDs等临床表现异质性的疾病,使用NGS基因panel似乎有益。尽管检测到的变异数量较多,但临床诊断率仍然较低。这些疾病的基因型 - 表型关系仍不清楚。